Related Experiment Video
Updated: Jan 23, 2026

Identification of Fatty Acids in Bacillus cereus
Published on: December 5, 2016
Cardiovascular, electrophysiologic, and hematologic effects of omega-3 fatty acids beyond reducing
Omar Sheikh1, Anthony G Vande Hei2, Ayman Battisha3
1Cardiology Division, University Texas Health Science Center at San Antonio, 7403 Wurzbach Road, San Antonio, TX, 78229, USA. sheikho@uthscsa.edu.
Insights
Highly purified eicosapentaenoic acid (EPA) ethyl ester significantly reduced cardiovascular events in the REDUCE-IT trial. This study explores the molecular mechanisms behind EPA
Area of Science:
- Cardiovascular Medicine
- Molecular Biology
- Pharmacology
Background:
- Heart disease remains a leading cause of death globally, with high residual risk despite guideline-directed medical therapy.
- The clinical benefits of omega-3 polyunsaturated fatty acids in cardiac disease have been historically debated.
- The REDUCE-IT trial showed significant risk reduction with icosapent ethyl, a purified eicosapentaenoic acid (EPA) ethyl ester.
Purpose of the Study:
- To elucidate the molecular mechanisms of action for purified EPA ethyl ester.
- To enhance understanding of the clinically observed effects of EPA in cardiovascular disease.
- To address the under-discussed mechanisms behind omega-3 fatty acid efficacy.
Main Methods:
- Review and synthesis of existing literature on omega-3 fatty acid biochemistry and pharmacology.
- Analysis of molecular pathways potentially modulated by purified EPA ethyl ester.
- Correlation of molecular actions with clinical outcomes observed in trials like REDUCE-IT.
Main Results:
- Icosapent ethyl demonstrated a 4.8% absolute risk reduction in major adverse cardiovascular events.
- Potential mechanisms include modulation of inflammation, lipid metabolism, and plaque stability.
- Increased incidence of atrial fibrillation and a trend towards increased bleeding risk were noted.
Conclusions:
- Understanding the molecular basis of EPA action is crucial for optimizing its clinical application.
- Purified EPA ethyl ester offers significant cardiovascular benefits, but potential risks require careful consideration.
- Further research into EPA's molecular targets can refine therapeutic strategies for heart disease.
Abstract:
Heart disease continues to affect health outcomes globally, accounting for a quarter of all deaths in the United States. Despite the improvement in the development and implementation of guideline-directed medical therapy, the risk of adverse cardiac events remains substantially high. Historically, it has been debated whether omega-3 polyunsaturated fatty acids provide clinical benefit in cardiac disease. The recently published REDUCE-IT trial demonstrated a statistically significant absolute risk reduction of 4.8% in its primary endpoint (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina) with the use of icosapent ethyl, which is a highly purified eicosapentaenoic acid (EPA) ethyl ester. However, the mechanism of action of omega-3 fatty acids is not commonly discussed. Moreover, the use of EPA was not without risk, as the incidence of atrial fibrillation was increased along with a trend towards increased bleeding risk. Thus, our aim is to help explain the function of purified EPA ethyl ester, especially at the molecular level, which will ultimately lead to a better understanding of their clinically observable effects.
Related Concept Videos
Reducing Line Loss
With a step-up transformer at the source, the voltage is increased, thereby reducing the current in the transmission lines since power loss in...
Methods of reducing fever
Pharmacological Methods of Reducing Fever:
Adaptations that Reduce Water Loss
Role of Reduced Coenzymes NADH and FADH₂
Redox Titration: Other Oxidizing and Reducing Agents
Reduced Mass Coordinates: Isolated Two-body Problem

